INTENDD® is our proprietary in silico drug design strategy that enables us to screen around 10 million chemical compounds (commercial libraries and PPI-oriented in-house compounds).

Screening by INTENDD® is comprised of 2 steps:

1) Identification of binding pockets for small molecule (1 month)

2) Molecular design based on “binding mechanism” by SBSG® (Structure-Based Scaffold Generation) method (3 months).

Home page of this offering   provided by Interprotein Corporation